Interferon alpha 2b in the treatment of uveitic cystoid macular edema

Nicholas J. Butler, Eric B. Suhler, James T. Rosenbaum

Research output: Contribution to journalReview article

Abstract

Purpose: To determine the efficacy of interferon alpha 2b in the treatment of refractory, uveitic cystoid macular edema (CME). Methods: Retrospective chart review of 4 patients attending the uveitis clinic at the Casey Eye Institute, Oregon Health & Science University. Results: All 4 patients had uveitis and refractory CME, resistant to a variety of immunosuppressants. All patients, except one with severe scleral thinning, had tried and failed therapy with locally injected corticosteroids. Treatment with systemic interferon alpha 2b produced dramatic improvement in CME (central macular thickness: 563 to 267m, p=.002) and visual acuity (logMAR: +0.81 to +0.45, p=.0004) in all 4 cases. All patients have been able to reduce the interferon dosage, but none has discontinued it completely. All patients had some mild adverse response that did not necessitate stopping therapy. Conclusions: Interferon alpha 2b is an effective option to treat refractory CME secondary to uveitis.

Original languageEnglish (US)
Pages (from-to)86-90
Number of pages5
JournalOcular Immunology and Inflammation
Volume20
Issue number2
DOIs
StatePublished - Apr 1 2012

Keywords

  • Cystoid
  • Edema
  • Interferon alpha 2b
  • Macular
  • Uveitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Ophthalmology

Fingerprint Dive into the research topics of 'Interferon alpha 2b in the treatment of uveitic cystoid macular edema'. Together they form a unique fingerprint.

  • Cite this